GSK announces acquisition of RAPT Therapeutics for 2.2 billion dollars

GSK announced the acquisition of U.S.-based RAPT Therapeutics for $2.2 billion on Tuesday. This represents a significant capital deployment for the firm.

洞察:
GSK plc announced on Tuesday, January 20, 2026, that it has reached an agreement to acquire RAPT Therapeutics Inc for $2.2 billion. As reported by Reuters, this acquisition represents a significant capital deployment by the pharmaceutical company to expand its therapeutic portfolio. The transaction scale and its immediate market impact make this a material corporate event for both companies and their respective shareholders.
FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/File Photo
FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/File Photo
IUX24

IUX24 提供深度財經、經濟與投資資訊,借助 AI 挖掘全球市場中最重要的訊號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場資料、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易訊號或經紀服務。投資涉及風險,使用者在做出投資決定前應審慎評估相關資訊。